Tanzania 2026 Regulatory Updates: PMS, MDSAP and Retention Fees

1. Key takeaways

In the second half of 2026 the TMDA issued three device-related documents within two months, and together they form a clear policy signal: the regulatory centre of gravity is shifting from pre-market approval towards post-market continuous compliance and the acceptance of quality system evidence. Each document reinforces a different dimension of the licence holder’s obligations, and none of them introduces a new statutory duty; they operationalise duties that have existed since 2015.

2. Legal basis

3. Expert insights

Insight 1: the three developments fall on three different dimensions — post-market obligations, acceptance of system evidence and fiscal obligations — and together they form one complete policy line.

• The PMS report (August) → concretises the post-market data obligation;
• MDSAP (September) → international acceptance of pre-market system evidence;
• The retention fee notice (October) → an annualised reminder of the fiscal obligations of holding a licence.

Taken together, the three developments show that Tanzania is stretching the compliance horizon from the moment of obtaining the certificate to the entire life cycle of holding it. Companies that only invest effort at approval time are now exposed on three additional fronts, each with its own calendar and evidence requirements.

Insight 2: publishing the next year’s payment notice in October is a predictable operating rhythm.

The TMDA issued the 2027 retention fee notice on 1 October 2026, while the statutory payment deadline is 31 January of the following year. In other words, companies have a preparation window of roughly four months, and the notice reliably appears around October of the preceding year. This rhythm can be written into the compliance calendar as a fixed trigger, with internal payment approval started immediately after the notice rather than waiting for the January deadline.

Insight 3: the wording of the PMS notice is more specific than Article 17(3) of GN 315 and is the operative basis in practice.

Article 17(3) contains a single sentence (a biennial PMS report containing adverse events must be submitted); the 2026 notice expands it into nine categories of content (quality, safety and performance; adverse events and incidents; complaints; safety signals; FSCA; FSN; recalls; corrective actions; vigilance information, among others) and makes clear that the report does not replace immediate reporting. Companies should prepare according to the nine-category list of the notice, not according to the single sentence of Article 17(3). A report built on the statutory sentence alone would omit structured data the reviewer now expects to find.

Insight 4: the MDSAP status does not change the existing rule under which China is excluded.

Under the quality audit guidelines, §7.2.1.4 excludes Brazil and China under the MDSAP heading, and §7.2.1.2 excludes China, Brazil and Russia under the IMDRF member heading. The TMDA’s accession to MDSAP did not amend either exclusion. For manufacturers in China, the practical value of the September 2026 development is that the importance of system evidence has risen, not that a channel has opened. Scheduling and audit preparation should continue on the same basis as before.

Insight 5: none of the three developments changes written law; they are an intensification of enforcement.

Article 17(2) of GN 315 (retention fees) and Article 17(3) (PMS reports) have existed since 2015; the MDSAP status likewise changes no statutory duty. The three developments re-emphasise and refine existing obligations; they do not create new ones. This matters for prioritisation: companies should first close any gaps in discharging existing obligations rather than waiting for new rules. Compliance resources spent anticipating hypothetical new duties are resources not spent on the biennial PMS report or the January payment deadline, both of which are already enforceable.

4. Practical recommendations

1. Set October as the starting node for the next year’s retention fee work (the TMDA notice publication window).
2. Prepare the PMS report according to the nine-category list of the 2026 notice, not only according to Article 17(3).
3. Assemble notarised copies of quality system audit reports from the last 3 years (§7.2.2.4) to prepare for evidence acceptance once the MDSAP status takes practical effect.
4. Manufacturers in China should not change their scheduling because of the MDSAP development, and should continue to prepare for on-site audits (§7.2.1.2, §7.2.1.4).
5. Enter the three developments into the 2027 compliance calendar: 31 January retention fee, biennial PMS, 30 June premises licence, and the 5-year / 3-year renewals.

5. Verification checklist

• □ The dates of the three developments are recorded: 2026-08-17 (PMS), 2026-09-24 (MDSAP), 2026-10-01 (2027 retention fee).
• □ The PMS report is prepared according to the nine-category list of the notice.
• □ Notarised copies of quality system audit reports from the last 3 years have been assembled (§7.2.2.4).
• □ It has been confirmed that the MDSAP development does not change the rule under which China is excluded.
• □ The three developments have been entered into the 2027 compliance calendar.
• □ It has been confirmed that the three developments are an intensification at the enforcement level and introduce no new statutory duties.

Regulatory information verified as of 29 October 2026. All content cited in this document has been checked against the TMDA public notices (17 August 2026, 24 September 2026 and 1 October 2026), GN. No. 315 Articles 17 and 18, and the quality audit guidelines §7.2.1.2, §7.2.1.4 and §7.2.2.4; the review is repeated whenever the regulations are updated.

• Tanzania local resources: GRZAN can coordinate licensed local responsible persons (LRP) and distributor resources covering online submission, sample delivery, quality audit support and port clearance.
• Service capabilities: classification determination, registration and notification pathway selection, technical documentation (CSDT/STED) preparation and localization, GMDN and grouping strategy, clinical evidence organization, software and AI device submissions, change management, vigilance and PMS reporting, annual retention fee and renewal management.
• Contact: info@grzanglobal.com.